Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

49 results about "Synovial Cell" patented technology

A fibroblast that lies between the cartilaginous fibers in the synovial membrane of joints.

Organ chip unit, chip and research method

PendingCN119823867ATissue/virus culture apparatusCartilage cellsSynovial Cell
The invention provides an organ chip unit for simulating the pathogenesis of rheumatoid arthritis, and belongs to the technical field of cell culture. The chip comprises a top-layer chip, a bottom-layer chip and a middle microporous membrane, the top-layer chip and the bottom-layer chip are separated by the middle microporous membrane, and the middle microporous membrane is used for enabling cells in a cell culture space of the top-layer chip and cells in a cell culture space of the bottom-layer chip not to be in direct contact, but interaction of signal molecules and substance exchange can be carried out; synovial cells and cartilage cells are injected into the bottom-layer chip or the top-layer chip to be cultured. According to the invention, multi-cell three-dimensional co-culture can be realized. Through the additional stress stimulation co-culture part, the influence of pressure or tension on the cell environment can be judged, and the actual condition that rheumatoid arthritis joints receive pressure or tension for a long time can be simulated. The synovial cells and the cartilage cells are used, so that the structure of the inflammation joint in a living body can be truly reflected, and the interaction among various cell tissues can be reflected.
Owner:EAST CHINA UNIV OF SCI & TECH

Small molecule compound TII-C2 and application thereof in preparation of medicine for treating TRADD related autoimmune diseases

PendingCN119241525Aprevent proliferationability to inhibit migrationSenses disorderOrganic chemistryFibroblast-like synoviocyteAutoimmune condition
The invention discloses a small molecule compound TII-C2 and an application thereof in preparation of a medicine for treating TRADD related autoimmune diseases. According to the present invention, the combination of the small molecule compound TII-C2 and TRADD can destroy the combination of TRADD and TRAF2, significantly inhibit the activation of a TNFR1 downstream signal channel, and inhibit the abnormal proliferation of fibroblast-like synovial cells, such that the clinical manifestation of an arthritis mouse model is improved, and the important reference is provided for the treatment of rheumatoid arthritis and TRADD-related autoimmune diseases; good application prospects are realized.
Owner:ANHUI MEDICAL UNIV

Drug targeting delivery system for targeting joint pathology fibroblast-like synovial cells and application of drug targeting delivery system

InactiveCN119700998APeptide/protein ingredientsAntipyreticFibroblast-like synoviocyteChemical reaction
The invention provides a universal drug targeting delivery system for constructing pathological fibroblast-like synovial cells in osteoarthritis and application of the universal drug targeting delivery system. According to the drug targeting delivery system, vasoactive intestinal peptide is modified to the surface of polydopamine-coated large-aperture calcium ion-doped silicon dioxide; the vasoactive intestinal peptide specifically targets a VPAC1 receptor, and targeted delivery of the nano-drug to pathological fibroblast-like synovial cells in osteoarthritis is successfully realized. The vasoactive intestinal peptide provided by the invention is a polypeptide, has abundant amino groups and carboxyl groups, and can be connected to a drug delivery carrier through a simple chemical reaction, so that efficient targeted delivery of drugs and accumulation of pathological cells are realized.
Owner:ZHEJIANG UNIV

Compounds that inhibit WNK2 activity and methods for treating osteoarthritis

PCT designated stageWO2026236654A1Skeletal disorderHeterocyclic compound active ingredientsSynovial CellOsteocyte
Described herein are compositions and their use in methods and pharmaceutical compositions for inhibiting WNK2 activity. Also, described herein are methods of using said compositions to treat osteoarthritis, ameliorate one or more symptoms of osteoarthritis, reduce pSPAK expression in damaged cartilage, bone, synovium, ligaments, tendons, fat pad, and other tissues of the synovial joint, and reducing WNK2 expression in chondrocytes, synovial cells, immune cells, ligaments, tenocytes, and adipocytes.
Owner:UNIV OF UTAH RES FOUND

EP300 detection preparation and application of EP300 in product for treating rheumatoid arthritis

PendingCN121294640AOrganic active ingredientsAntipyreticEP300Synovial Cell
The invention provides an EP300 detection preparation and application of EP300 in a product for treating rheumatoid arthritis, and relates to the technical field of biological medicines. The rheumatoid arthritis symptom is relieved by inhibiting EP300 gene expression, after EP300 is knocked down in human THP-1-derived macrophages, H3K18 lactylation expression is reduced, and after EP300 is knocked down in human THP-1-derived macrophages, EP300 and human synovial cells are co-cultured, so that the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, and the human THP-1-derived macrophages are obtained. Through the crosstalk effect between human THP-1-derived macrophages and human synovial cells, the expression of inflammatory markers MMP3 and Fibronectin in the synovial cells can be remarkably inhibited, compared with a model group, the proliferation capacity of the synovial cells is weakened, a potential treatment target is provided for treating rheumatoid arthritis, and the application has the advantages that the application is easy to popularize and use, and the application has a wide application prospect. The pathogenesis of rheumatoid arthritis is perfected, and hope is brought to research and development of novel biomarkers for early diagnosis, targeted therapy and prognosis evaluation of rheumatoid arthritis.
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE +1

A pharmaceutical composition for treating rheumatoid arthritis and use thereof

The application provides a pharmaceutical composition for treating rheumatoid arthritis, which is composed of paeoniflorin, glycyrrhizin, glycyrrhizic acid and glycyrrhetic acid in a weight ratio of (4.5-7.5):(0.4-1.8):(1.8-4.3):(22-40). The pharmaceutical composition can significantly inhibit the proliferation of fibroblast-like synoviocytes, reduce the secretion of inflammation-related factors (TNF-alpha, IL-1beta, IL-6 and COX-2), regulate the expression of TNF-alpha / NF-kappaB signal pathway-related proteins, and has a significant curative effect on rheumatoid arthritis.
Owner:BEIJING UNIV OF CHINESE MEDICINE

Method and system for detecting urate crystal deposition and phagocytosis in synovial organ tissue

The invention belongs to the technical field of medical detection, and particularly relates to a method and a system for detecting urate crystal deposition and phagocytosis in synovial organ tissues. The system comprises a synovial organ culture and verification module used for obtaining a human synovial sample, performing synovial tissue culture and forming different synovial organs; the stimulated Raman scattering microscope imaging module is used for imaging the cultured synovial organs; specifically, a specific pump-Stokes wavelength combination, a spatial deposition quantitative analysis and detection module of urate crystals and a spatial phagocytosis quantitative analysis and detection module of urate crystals are adopted; according to the method, the spatial deposition conditions of urate crystals in different synovials and the phagocytosis of osteoarthritis synovial cells on the crystals can be effectively imaged, and the unit quantity density and the intensity density of deposited or phagocytosed crystals are quantitatively calculated and analyzed; therefore, guidance is provided for development of related basic research and clinical quantitative diagnosis of gout.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

Biomimetic carrier-free nanoparticle, preparation method and application

PendingCN122624419AGallic acid esterSynovial Cell
This invention relates to the field of pharmaceutical formulation and preparation and application technology, and particularly to a biomimetic carrier-free nanoparticle with synergistic effects of copper death and chemokinetics, its preparation method, and its application. The nanoparticle is constructed with a metallophenol network formed by the coordination self-assembly of gallic acid and copper ions, and coated with a neutrophil membrane. Copper ions can catalyze the generation of hydroxyl radicals from hydrogen peroxide through a Fenton-like reaction, inducing copper death in diseased synovial cells, thereby efficiently clearing inflammatory cells. Gallic acid exerts anti-inflammatory and antioxidant effects, synergistically regulating the inflammatory microenvironment. The neutrophil membrane endows the nanoparticle with the ability to actively target inflamed joints, effectively reducing off-target toxicity. The nanoparticles provided by this invention have advantages such as strong targeting, high biocompatibility, simple preparation, and a clear synergistic therapeutic mechanism, which can significantly improve the therapeutic effect of rheumatoid arthritis and reduce systemic toxic side effects.
Owner:MACAU UNIV OF SCI & TECH

Application of baicalein in preparation of medicine for delaying rheumatoid arthritis

PendingCN119157871AOrganic active ingredientsAntipyreticBaicaleinFibroblast-like synoviocyte
The invention belongs to the technical field of biological medicines, and particularly relates to application of baicalein in preparation of a medicine for delaying rheumatoid arthritis. The medicine in the application is a medicine for inhibiting the activity of the rheumatoid arthritis fibroblast-like synovial cells, and further, the medicine is a medicine for down-regulating the protein expression of NOX2 in the rheumatoid arthritis fibroblast-like synovial cells. In the application, the effective in-vivo medication concentration of the baicalein is 300-600 mg / kg, and the effective in-vitro medication concentration of the baicalein is 20-60 [mu] mol / L. According to the application, rheumatoid arthritis fibroblast-like synovial cells are taken as a research object, and baicalein is used for intervening cell viability and functions by down-regulating NOX2, so that the rheumatoid arthritis is relieved.
Owner:SHANDONG YIKANG PHARM CO LTD

Soluble epoxide hydrolase inhibitor, pharmaceutical composition, pharmaceutical preparation and application thereof

PendingCN121293149AOrganic active ingredientsOrganic chemistryFibroblast-like synoviocyteSynovial Cell
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a soluble epoxide hydrolase inhibitor, a pharmaceutical composition, a pharmaceutical preparation and application of the soluble epoxide hydrolase inhibitor in rheumatoid arthritis drugs. The invention provides a soluble epoxide hydrolase inhibitor which is a compound shown in a formula (I) or a tautomer, a stereoisomer, a hydrate, a solvate, a crystal form, a pharmaceutically acceptable salt or a prodrug thereof, and substituent groups R1-R23 are defined in the text. The soluble epoxide hydrolase inhibitor provided by the invention can remarkably inhibit proliferation, migration and invasion of fibroblast-like synovial cells, promote apoptosis of the fibroblast-like synovial cells and relieve the symptoms of rheumatoid arthritis, has relatively low side effects, and can prolong the half-life period of a drug in vivo.
Owner:PEKING UNIVERSITY SHENZHEN HOSPITAL +1

Application of green tendon relaxing ketone in preparation of medicine for treating rheumatoid diseases

The invention discloses an application of green tendon relaxing ketone in preparation of a medicine for treating rheumatoid diseases. The invention proposes and verifies that the green tendon relaxing ketone can effectively promote fibroblast-like synovial cell ferroptosis so as to inhibit synovial hyperplasia and inhibit the expression of proinflammatory cytokines so as to effectively relieve the progress of rheumatoid arthritis for the first time, and has an excellent application prospect in clinical treatment of rheumatoid diseases.
Owner:NANTONG UNIV

Synovial extracellular matrix specific chimeric antigen receptors for targeting regulatory t cells to treat autoimmune diseases

Disclosed herein are chimeric antigen receptors ("CARs") comprising an antigen binding site that recognizes a citrullinated polypeptide. A citrullinated polypeptide, such as citrullinated waveform protein, fibrinogen, and polyfibroin, is expressed in the synovium of a subject suffering from rheumatoid arthritis. Further disclosed are T cells, and in particular Treg cells, expressing these CARs. Administration of these CAR-T cells may be used to treat rheumatoid arthritis as well as other diseases associated with citrullinated peptides.
Owner:SONOMA BIOTHERAPEUTICS INC +1

Effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis in humans, and compositions comprising the same

ActiveUS12714755B2White blood cellSynovial Cell
The disclosure relates to pharmaceutical compositions and methods of using pharmaceutical compositions comprising effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (IL-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (IL-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (IL-1Ra) gene within synovial cells is regulated by an inflammation-sensitive promoter.
Owner:PACIRA THERAPEUTICS INC

An intra-articular preparation containing a chitosan-based lidocaine and a method for preparing the same

This invention discloses a chitosan-based lidocaine formulation for intra-articular use and its preparation method. Belonging to the field of pharmaceutical formulation technology, the formulation is prepared from chitosan, carboxymethyl chitosan, lidocaine, chitosan-PNIPAM microspheres, sulfated trehalose, and excipients. The chitosan-PNIPAM used in this invention exhibits dual temperature and pH response. With temperature changes, PNIPAM possesses both hydrophobic contractile and hydrophilic swelling states, thereby controlling the lidocaine release rate. Simultaneously, when the pH decreases, chitosan repels PNIPAM, further disintegrating the microspheres to release the drug, thus achieving targeted analgesia. Sulfated trehalose, as a cartilage matrix synthesis promoter, can activate intracellular signaling pathways in chondrocytes, promoting the synthesis of type II collagen and proteoglycans. Simultaneously, the sulfate groups can form electrostatic complexes with the amino groups of chitosan, enhancing drug retention. The formulation of this invention can inhibit synovial cells, release cytokines, and synergistically with carboxymethyl chitosan, increase the inhibition rate of inflammatory factors by 40%-50%.
Owner:SHANDONG MIANYITONG MEDICAL TECHNOLOGY CO LTD

Use of PT-129 in the preparation of a medicament for treating rheumatoid arthritis

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.
Owner:THE SECOND AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV

Oligonucleotide hydrogel micro-nano gene compound as well as preparation method and application thereof

PendingCN121177515AOrganic active ingredientsAntipyreticFibroblast-like synoviocyteSynovial Cell
The invention provides an oligonucleotide hydrogel micro-nano gene compound as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method comprises the following steps: firstly, designing C5ASO, and loading the C5ASO on a nano-carrier modified with HAP-1 peptide (targeting fibroblast-like synovial cells) and active ester; meanwhile, the porous HAMA hydrogel microspheres are prepared by utilizing a photo-crosslinking micro-fluidic technology; then, DBCO-TIMP and an azide group are respectively introduced into the liposome and the hydrogel microspheres through Michael addition and an amide coupling reaction, so that a micro-nano gene compound (C5ASO (at) HAP-CL-TIMP (at) HMs) is formed; in addition, the liposome and the hydrogel microspheres are efficiently compounded through click chemistry. The hydrogel micro-nano gene compound not only can efficiently load ASO lipidosome, but also can enhance the stability of a gene therapeutic agent in an in-vivo delivery process. Meanwhile, the MMP-9 response peptide structure in the RA articular cavity inflammation microenvironment can be accurately activated, so that continuous complement intervention is realized.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1

Use of oridonin in preparation of a medicine for preventing and / or treating rheumatoid arthritis synovitis

The application belongs to the technical field of biological medicine, and discloses application of oridonin in preparation of a medicine for treating rheumatoid arthritis synovitis. For the first time, it is confirmed that oridonin takes glyceraldehyde-3-phosphate dehydrogenase as a direct action target, covalently combines through an α, β-unsaturated ketone, inhibits enzyme activity, blocks abnormal glycolysis of rheumatoid arthritis synovial cells, activates a KEAP1-NRF2 / HO-1 antioxidant anti-inflammatory pathway, inhibits an NF-κB inflammatory signal, and intervenes in a pathological process of rheumatoid arthritis synovitis from multiple dimensions, thereby providing a scientific basis for clinical application and deep development of oridonin against RA synovitis. A medicine composition containing oridonin and application of the medicine composition in preparation of an anti-rheumatoid arthritis synovitis medicine are disclosed. The application has advantages of target point precision, remarkable curative effect, high safety, mechanism innovation and the like, and provides a brand-new scheme for clinical treatment of rheumatoid arthritis synovitis.
Owner:CHENGDU UNIV

Use of sema3e protein in preparation of drugs for treating rheumatoid arthritis and promoting cartilage regeneration

The application provides application of SEMA3E protein in preparation of a drug for treating rheumatoid arthritis and promoting cartilage regeneration, and belongs to the technical field of biological medicine. The amino acid sequence of the SEMA3E protein is shown as SEQ ID No. 1. Research results show that one month after injection of the SEMA3E protein solution, the joint swelling degree of the double hind limbs of an animal model is reduced, the joint space and integrity are restored to normal, the cartilage thickness is increased, and the phenomenon of synovial cell infiltration and invasion into the cartilage is eliminated. That is, the SEMA3E protein can well reduce joint cavity inflammation and improve damaged joints.
Owner:KUNMING UNIV OF SCI & TECH

New use of m6a modification gene GAS6 and its receptor MERTK in rheumatoid arthritis

The application discloses a new application of m6A modified gene GAS6 and its receptor MERTK in rheumatoid arthritis. Multi-omics integrated analysis of synovial tissue and peripheral blood mononuclear cells of RA patients reveals common dysregulation of transcriptomics and epitranscriptomics, highlighting genes with both differential expression and m6A modification, which are enriched in processes such as phagocytosis, Th17 differentiation and cell aging. Among these genes, GAS6 shows the most significant m6A hypermethylation and expression up-regulation, and is verified as a key effector molecule interacting with MERTK / AXL receptor. Functional experiments show that GAS6 and MERTK synergistically promote the malignant phenotype of RA fibroblast-like synoviocytes, enhance their proliferation, migration, inflammatory cytokine secretion and anti-apoptotic ability.
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Plant active ingredient for inhibiting inflammatory response of synovial cells and method for treating rheumatoid arthritis by using plant active ingredient

The invention relates to a plant active ingredient for inhibiting synovial cell inflammatory response and a method for treating rheumatoid arthritis by using the plant active ingredient. The active ingredient is selected from one or more of kaempferide, quercetin, luteolin and alpinetin sesquiterpenoids, and is derived from medicinal plants such as alpinia pumila, glabrous sarcandra herb or herba epimedii and the like. The high-purity flavonoid monomer is obtained through a specific extraction process including ethanol reflux extraction, ethyl acetate extraction, macroporous resin enrichment and silica gel column chromatography separation. The composition can remarkably inhibit activation of NF-kappa B signal channels in synovial cells in vitro, reduce expression levels of inflammatory factors TNF-alpha, IL-1beta and IL-6 and reduce generation of reactive oxygen species (ROS) and nitric oxide (NO), and has a good anti-rheumatic arthritis effect. The active component can be prepared into various dosage forms such as capsules, granules, injections and the like, and is suitable for treatment or adjuvant treatment of rheumatic arthritis and related diseases thereof.
Owner:QIANDONGNAN NAT POLYTECHNIC

Methotrexate-bletilla striata polysaccharide nanoparticles as well as preparation method and application thereof

ActiveCN120695007AOrganic active ingredientsPowder deliverySynovial CellSynoviocyte proliferation
The invention relates to the technical field of rheumatoid arthritis medicines, in particular to methotrexate-bletilla striata polysaccharide nanoparticles as well as a preparation method and application thereof. The invention provides methotrexate-bletilla striata polysaccharide nanoparticles. The methotrexate-bletilla striata polysaccharide nanoparticles have a structure as shown in a formula 1. The nanoparticle is formed by connecting methotrexate and bletilla striata polysaccharide through a disulfide bond, and theoretically, the nanoparticle can respond to high active oxygen stimulation in a rheumatoid arthritis microenvironment to realize drug release. In addition, the research proves that the nanoparticles can effectively inhibit proliferation and migration of fibroblast-like synovial cells, adjust polarization of M1 type macrophages to M2 type macrophages and relieve synovial inflammation. The methotrexate-bletilla striata polysaccharide nanoparticles are simple in preparation process operation and convenient to use, and have good development and utilization prospects. Formula 1
Owner:QIQIHAR MEDICAL UNIVERSITY

Use of sesquiterpenes in the preparation of drugs for regulating synoviocytes

PendingCN122163598AOrganic active ingredientsSkeletal disorderInflammatory factorsFibroblast-like synoviocyte
The application belongs to the technical field of medicine, and discloses application of a sesquiterpenoid compound in preparation of a drug for regulating synovial cells. The application first discloses a triple regulation mechanism of CJB on fibroblast-like synovial cells, i.e. inhibiting cell proliferation, reducing inflammatory reaction, and regulating ferroptosis pathway. Compared with a single-target drug, the multi-target effect mode can more comprehensively control the pathological process of RA, not only inhibits abnormal proliferation of FLS and secretion of inflammatory factors, but also removes pathological synovial cells by regulating ferroptosis and apoptosis, significantly improves the treatment effect, and reduces disease recurrence. Moreover, CJB has low toxicity, raw materials are easy to obtain, and can be used in combination with existing anti-rheumatic drugs, thereby reducing drug side effects and treatment costs.
Owner:SUN YAT SEN UNIV

Novel RA (rheumatoid arthritis) marker long-chain non-coding RNA (ribonucleic acid) and application thereof in rheumatoid arthritis

The invention discloses a novel RA (rheumatoid arthritis) marker long-chain non-coding RNA (ribonucleic acid) and application thereof in rheumatoid arthritis, and belongs to the field of molecular biology of rheumatism. The new RA marker long-chain non-coding RNA, namely LINC00837, can promote the proliferation and migration of rheumatoid arthritis fibroblast-like synovial cells and the secretion of anti-inflammatory factors, so that the RA marker long-chain non-coding RNA can be used as a diagnostic preparation and a therapeutic preparation for rheumatoid arthritis. According to the sequence of the long-chain non-coding RNA, specific real-time quantitative PCR primers and probes are designed and synthesized, and a preparation for auxiliary diagnosis or curative effect prediction of RA is prepared. A real-time quantitative PCR preparation is utilized to detect the expression level of the long-chain non-coding RNA in an RA clinical case specimen, the expression of the long-chain non-coding RNA in the RA is obviously up-regulated, and the long-chain non-coding RNA is expected to be prepared into a preparation for auxiliary diagnosis or curative effect prediction of the RA.
Owner:FIRST AFFILIATED HOSPITAL OF ANHUI UNIV OF CHINESE MEDICINE

An engineered exosome and a preparation method and application thereof

The application relates to an engineered exosome and a preparation method and application thereof, wherein the engineered exosome comprises a natural exosome, a photosensitizer and miR451a loaded in the natural exosome, and an anti-FAP alpha antibody or an antibody fragment loaded on the surface of the natural exosome; the anti-FAP alpha antibody is used for guiding the target receptor cell of the engineered exosome to be combined; the photosensitizer and the miR451a participate in the occurrence of ferroptosis of the target receptor cell under the action of photodynamic effect; and the target receptor cell is an activated fibroblast-like synoviocyte in rheumatic lesions. The application has the beneficial effects of providing a synergistic scheme of "biological carrier + physical stimulation" for RA treatment and having the treatment characteristics of high efficiency, low toxicity and high targeting.
Owner:SHANXI BETHUNE HOSPITAL (SHANXI ACAD OF MEDICAL SCI SHANXI HOSPITAL OF TONGJI HOSPITAL AFFILIATED TO TONGJI MEDICAL COLLEGE OF HUAZHONG UNIV OF SCI & TECH SHANXI MEDICAL UNIV THIRD HOSPITAL SHANXI MEDICAL UNIV THIRD CLINICAL COLLEGE OF MEDICINE) +1

Application of benzyl piperidine compound in preparation of medicine for treating gout

ActiveCN121059603AOrganic active ingredientsSkeletal disorderDiseaseFibroblast-like synoviocyte
The invention discloses an application of a benzyl piperidine compound in preparation of a medicine for treating gout, by constructing a sodium urate-induced gout rat model and a sodium urate-induced fibroblast-like synovial cell model, 25 mg / kg / day of the benzyl piperidine compound is found to significantly reduce the ankle joint swelling degree and synovial hyperplasia of a gout rat; the 1.8 [mu] M benzyl piperidine compound starts to significantly inhibit the activity of human primary fibroblast-like synovial cells induced by sodium urate, and the 3.6 [mu] M benzyl piperidine compound significantly inhibits the invasion and migration ability of rat primary fibroblast-like synovial cells induced by sodium urate. In-vivo and in-vitro pharmacological experiments prove that the benzyl piperidine compound disclosed by the invention has a good gout treatment effect, can be used for preventing and treating gout diseases, and has a relatively high clinical application value.
Owner:THE SECOND AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV

Topical formulation for binding to dermatological cannabinoid receptors

PendingUS20260144840A1Aerosol deliveryOintment deliverySynovial CellMucosal inflammation
A topical cream or ointment is provided that provides for the binding to CB1 and / or CB2 receptors for the soothing of pain, inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, peripheral nerve fibers, reduction of endothelial bruising, promotion of healing of endothelial bruising, and dermatological itch sensation wherein the improvement comprises providing the effect of cannabinoid using plant extracts. A topically administered formulation is also provided for treating anal mucosal inflammation, soothing of pain, inflammation of anal mucosal inflammation; reducing keratinocyte apoptosis; treating viral-associated epithelial damage, treating radiation dermatitis; and treating chemotherapy-induced dermatitis.
Owner:KADO JESSICA

Application of D-dopa pigment isomerase inhibitor in preparation of medicine for treating rheumatoid arthritis

PendingCN121337999AOrganic active ingredientsSkeletal disorderDiseaseFibroblast-like synoviocyte
The invention discloses application of a D-dopa pigment isomerase inhibitor in preparation of a medicine for treating rheumatoid arthritis, and belongs to the technical field of biological medicine. The invention defines that D-DT is an independent and key driving factor for rheumatoid arthritis, especially for the pathological behavior of fibroblast-like synovial cells. The specific molecular mechanism that D-DT plays a role in FLS through an MAPK signal path-COX-2 / PGE2 signal axis is systematically clarified for the first time, and a complete'target spot-pathway-function 'chain is formed. In-vitro and in-vivo experiments prove that selective inhibition of D-DT can effectively relieve disease symptoms and pathological progression, and solid principle verification is provided for development of a new therapy.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV

Ardisia gigantifolia leaf extract, preparation method thereof and application of ardisia gigantifolia leaf extract in preparation of medicine for preventing and treating gouty arthritis

PendingCN121360150AAntipyreticAnalgesicsBiotechnologySynovial Cell
The invention discloses a giantleaf ardisia rhizome leaf extract, a preparation method thereof and application of the giantleaf ardisia rhizome leaf extract in preparation of medicines for preventing and treating gouty arthritis. The method comprises the following steps: extracting leaves of giantleaf ardisia rhizome with ethanol or an ethanol aqueous solution, dissolving an extract in water, and extracting with n-hexane and ethyl acetate in sequence to obtain an ethyl acetate extract, namely the giantleaf ardisia rhizome leaf extract. The treatment potential of the AK leaves on gouty arthritis is systematically evaluated for the first time, and it is found that the ethyl acetate component (EF) of the AK leaves has the remarkable effects of resisting inflammation, relieving synovial cell apoptosis and protecting cartilage. Through network pharmacological analysis, the AK is identified to have a multi-target and multi-channel anti-inflammatory mechanism. The medicinal value of the AK leaves is disclosed, a new normal form is provided for sustainable utilization of wild medicinal plants, and the dual innovative significance of ecological protection and drug development is considered.
Owner:SOUTH CHINA BOTANICAL GARDEN CHINESE ACADEMY OF SCI

Application of total glucosides of paeony in preparation of medicine for preventing and / or treating gout

PendingCN119818568AAntipyreticAnalgesicsSynovial CellAllergic reaction
The invention relates to the technical field of medicines, and discloses application of total glucosides of paeony in preparation of medicines for preventing and / or treating gout. According to the application, the total glucosides of paeony can inhibit inflammation through AMPK, so that the effect of preventing and / or treating gout is realized. The total glucosides of paeony can reduce adverse reactions such as gastrointestinal reactions and anaphylactic reactions in gout attack prevention treatment and increase treatment compliance of patients, the occurrence rate of abnormal liver functions caused by the total glucosides of paeony is relatively low, and more treatment possibilities are provided for reducing uric acid and preventing gout attack of patients with hepatic and renal insufficiency; the total glucosides of paeony have a certain uric acid reducing effect, and can reduce proliferation of synovial cells and infiltration of inflammatory cells, protect joint structures and improve prognosis of gout patients by adjusting immunity and anti-inflammatory effects.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

Tibetan medicine spray for diminishing inflammation and relieving pain and preparation method thereof

PendingCN120678830AAntipyreticAnalgesicsSynovial CellCartilage repair
The invention discloses a Tibetan medicine spray for diminishing inflammation and relieving pain and a preparation method thereof. The preparation method comprises the following steps: 1, washing and airing; 2, pretreatment: soaking the Artemisia villosa in the highland barley wine, and supplementing with the fructus chebulae; 3, taking ethanol with the concentration of 55%-80%, and soaking the Artemisia villosa obtained in the step 2 and the oxytropis into an ethanol solution; 4, ultrasonic extraction and ethanol volatilization; and 5, blending to a proper concentration to obtain the spray. The Tibetan two-ingredient black medicine spray has the advantages that 1, the Tibetan two-ingredient black medicine spray has the specific effects of relieving arthralgia and swelling, improving joint functions, reducing inflammation indexes and the like on rheumatoid arthritis; 2, immune inflammatory response can be regulated, abnormal proliferation of joint synovial cells is inhibited, and cartilage repair is promoted;
Owner:TIBET TIBETAN MEDICAL UNIV